| Drug Type AAV based gene therapy | 
| Synonyms Adeno-associated virus 9 vector expressing a functional human codon optimized cDNA encoding MMAB (NIH/NCATS) | 
| Target | 
| Action modulators | 
| Mechanism MMAB modulators(metabolism of cobalamin associated B modulators) | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| RegulationOrphan Drug (United States) | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Methylmalonic Acidemia | Preclinical | United States  | 16 Oct 2024 | |
| Methylmalonic Acidemia | Preclinical | United States  | 16 Oct 2024 | 





